专利号:US-2024262834-A1 优先权日:2021-05-28 标 题:Synthesis of btk inhibitor and intermediates thereof 发明人:CHEN YONGGANG; CORRY JAMES; DESMOND RICHARD; DI MASO MICHAEL J; FORSTATER JACOB H; KUETHE JEFFREY T; KUHL NADINE; LARSON REED; LEVESQUE FRANCOIS; NARSIMHAN KARTHIK; OTTE DOUGLAS; PRIER CHRISTOPHER K; SHEVLIN MICHAEL; SIROTA ERIC; TAN LUSHI; THAISRIVONGS DAVID A; TURNBULL BEN W H; WANG ZHIXUN; XIAO KAIJIONG 权利人:MERCK SHARP & DOHME LLC 摘要:The present invention relates to efficient synthetic processes useful in the preparation of Compound A, a BTK inhibitor of Formula (I): or a pharmaceutically acceptable salt thereof, including the preparation of intermediates used to make Compound A or a pharmaceutically acceptable salt thereof.
专利号:US-12441733-B2 优先权日:2018-03-26 标题:Substituted 2,4-dioxotetrahydropyrimidines as intermediates in the synthesis of bruton's tyrosine kinase inhibitors 发明人:ARISTA LUCA; HEBACH CHRISTINA; HOLLINGWORTH GREGORY JOHN; HOLZER PHILIPP; IMBACH-WEESE PATRICIA; LORBER JULIEN; MACHAUER RAINER; SCHMIEDEBERG NIKO; VULPETTI ANNA; ZOLLER THOMAS 权利人:NOVARTIS AG 摘要:The invention relates to compounds of the formulae (I), (III), (IIIa), (XXIa), (XXIII), and/or (XLVI)or a pharmaceutically acceptable salt thereof, wherein the substituents are as defined in the specification; to intermediates in the preparation of the compounds, to pharmaceutical compositions comprising the compounds and to use of the compounds in the treatment of disease.
专利号:AU-2022280865-A1 优先权日:2021-05-28 标 题 :Synthesis of btk inhibitor and intermediates thereof
专利号:WO-2022251404-A1 优先权日:2021-05-28 标 题:Synthesis of btk inhibitor and intermediates thereof
专利号:AU-2022280865-A9 优先权日:2021-05-28 标 题:Synthesis of btk inhibitor and intermediates thereof
专利号:EP-4347599-A1 优先权日:2021-05-28 标 题:Synthesis of btk inhibitor and intermediates thereof
1: Woyach JA, Stephens DM, Flinn IW, Bhat SA, Savage RE, Chai F, Eathiraj S, Reiff SD, Muhowski EM, Granlund L, Szuszkiewicz L, Wang W, Schwartz B, Ghori R, Farooqui MZH, Byrd JC. First-in-Human Study of the Reversible BTK Inhibitor Nemtabrutinib in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia and B-Cell Non-Hodgkin Lymphoma. Cancer Discov. 2024 Jan 12;14(1):66-75. doi: 10.1158/2159-8290.CD-23-0670. 15(1):166. doi: 10.1186/s13045-022-01386-1. 3: Odetola O, Ma S. Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL). Curr Hematol Malig Rep. 2023 Oct;18(5):130-143. doi: 10.1007/s11899-023-00700-z. Epub 2023 Jun 6. 4: Rivera NR, Zewge D, Arvary R, Lin M, Lohani S. Development and validation of a GC method for a key nemtabrutinib intermediate: Implementation of an in-situ free base sample preparation protocol. J Pharm Biomed Anal. 2024 Apr 15;241:116002. doi: 10.1016/j.jpba.2024.116002. Epub 2024 Feb 1. 14(22):8247. doi: 10.3390/jcm14228247.
合成参考文献
参考文献:10.1182/bloodadvances.2022008121 摘要:Lim YS, Yoo SM, Patil V, Kim HW, Kim HH, Suh B, Park JY, Jeong NR, Park CH, Ryu JH, Lee BH, Kim P, Lee SH. Orally bioavailable BTK PROTAC active against wild-type and C481 mutant BTKs in human lymphoma CDX mouse models. Blood Adv. 2023 Jan 10;7(1):92–105. 参考文献:10.1016/j.ejmech.2023.115403 摘要:Chen S, Chen Z, Lu L, Zhao Y, Zhou R, Xie Q, Shu Y, Lin J, Yu X, Wang Y. Discovery of novel BTK PROTACs with improved metabolic stability via linker rigidification strategy. European Journal of Medicinal Chemistry. 2023 Jul;255():115403. doi: 10.1016/j.ejmech.2023.115403.